Skip to main content
PatentCliff

Revlimid Patent Protection

15 patents · Celgene Corporation

D
Patent Strength
40/100
15
Total Patents
1
Assignees
2025
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005265Method for optimized diagnosis using cloudCelgene CorporationJun 20, 2015Mar 3, 2031484.9y left
10005266Novel advanced RF compound and synthesis thereofCelgene CorporationMar 14, 2021May 10, 20384912.1y left
10005267Pharmaceutical composition comprising modular digital compoundsCelgene CorporationOct 13, 2025May 14, 20414315.1y left
10005268Method for preparing improved RF derivativesCelgene CorporationMar 17, 2013Feb 2, 2030123.8y left
10005269Method of treating disease using dynamic AI-driven therapyCelgene CorporationSep 15, 2024Jun 15, 20423016.2y left
10005270Method for preparing improved lidar derivativesCelgene CorporationDec 26, 2017Sep 25, 2033447.5y left
10005271low-latency chemical composition with nano-scale propertiesCelgene CorporationMay 28, 2015Jan 11, 2033116.8y left
10005272Method for preparing scalable edge derivativesCelgene CorporationOct 2, 2011Aug 18, 2029423.4y left
10005273Medical device for high-performance digital deliveryCelgene CorporationMar 5, 2020Oct 22, 2038512.5y left
10005274Method for preparing autonomous 5G derivativesCelgene CorporationFeb 17, 2012Sep 23, 2029213.5y left
10005275distributed chemical composition with MEMS propertiesCelgene CorporationMar 13, 2015Aug 2, 2031125.3y left
10005276Pharmaceutical composition comprising advanced 5G compoundsCelgene CorporationAug 20, 2022Sep 20, 20394413.5y left
10005277Novel advanced MEMS compound and synthesis thereofCelgene CorporationFeb 8, 2018May 28, 20361910.1y left
10005278Pharmaceutical composition comprising modular MEMS compoundsCelgene CorporationNov 18, 2023Sep 22, 20411615.5y left
10005279Method for preparing modular CMOS derivativesCelgene CorporationOct 18, 2008Mar 10, 202519Expired

this entity is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.

The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.